Analysts forecast that Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) will post sales of $18.80 million for the current quarter, Zacks reports. Three analysts have issued estimates for Keryx Biopharmaceuticals’ earnings. The highest sales estimate is $19.14 million and the lowest is $18.44 million. Keryx Biopharmaceuticals posted sales of $6.34 million during the same quarter last year, which suggests a positive year-over-year growth rate of 196.5%. The business is expected to report its next quarterly earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Keryx Biopharmaceuticals will report full-year sales of $18.80 million for the current financial year, with estimates ranging from $67.24 million to $74.37 million. For the next financial year, analysts anticipate that the business will post sales of $141.32 million per share, with estimates ranging from $115.58 million to $157.46 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Keryx Biopharmaceuticals.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.60). Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The company had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.51 million. During the same period last year, the business earned ($0.42) EPS. The firm’s quarterly revenue was up 62.4% compared to the same quarter last year.
A number of analysts have recently commented on the company. BidaskClub upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Cowen and Company restated a “hold” rating on shares of Keryx Biopharmaceuticals in a research note on Saturday, June 17th. Maxim Group reaffirmed a “buy” rating and issued a $9.00 price target on shares of Keryx Biopharmaceuticals in a report on Thursday, July 20th. ValuEngine cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. Finally, Zacks Investment Research cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, September 14th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $7.48.
Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 7.95 on Tuesday. Keryx Biopharmaceuticals has a 1-year low of $4.11 and a 1-year high of $8.38. The company’s market cap is $944.06 million. The stock has a 50 day moving average price of $7.19 and a 200 day moving average price of $6.72.
A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Keryx Biopharmaceuticals by 5.1% in the second quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock worth $52,043,000 after acquiring an additional 349,521 shares during the period. State Street Corp grew its position in Keryx Biopharmaceuticals by 20.1% in the first quarter. State Street Corp now owns 3,479,370 shares of the biopharmaceutical company’s stock worth $21,432,000 after acquiring an additional 582,624 shares during the period. Rice Hall James & Associates LLC grew its position in Keryx Biopharmaceuticals by 24.3% in the second quarter. Rice Hall James & Associates LLC now owns 1,666,934 shares of the biopharmaceutical company’s stock worth $12,052,000 after acquiring an additional 326,285 shares during the period. Northern Trust Corp grew its position in Keryx Biopharmaceuticals by 6.9% in the second quarter. Northern Trust Corp now owns 1,089,860 shares of the biopharmaceutical company’s stock worth $7,881,000 after acquiring an additional 70,420 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Keryx Biopharmaceuticals by 3.5% in the second quarter. Bank of New York Mellon Corp now owns 963,054 shares of the biopharmaceutical company’s stock worth $6,963,000 after acquiring an additional 32,687 shares during the period. Institutional investors own 65.19% of the company’s stock.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.